LFCR logo

Lifecore Biomedical, Inc. Stock Price

NasdaqGS:LFCR Community·US$292.2m Market Cap
  • 2 Narratives written by author
  • 0 Comments on narratives written by author
  • 2 Fair Values set on narratives written by author

LFCR Share Price Performance

US$7.80
0.93 (13.54%)
US$8.75
Fair Value
US$7.80
0.93 (13.54%)
10.9% undervalued intrinsic discount
US$8.75
Fair Value
Price US$7.80
AnalystConsensusTarget US$8.75
AnalystLowTarget US$7.50

LFCR Community Narratives

AnalystConsensusTarget·
Fair Value US$8.75 10.9% undervalued intrinsic discount

Biopharma Partnerships And Injectable Demand Will Expand Global Reach

0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AnalystLowTarget·
Fair Value US$7.5 4.0% overvalued intrinsic discount

Injectable Manufacturing Demand And Regionalization Trends Will Support Steady Long Term Earnings Improvement

0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
US$7.5
4.0% overvalued intrinsic discount
Revenue
6.13% p.a.
Profit Margin
15.5%
Future PE
15.59x
Price in 2028
US$9.65

Trending Discussion

Updated Narratives

LFCR logo

LFCR: New Manufacturing Agreements Will Support Steadier Outlook With Balanced Prospects

Fair Value: US$8.75 10.9% undervalued intrinsic discount
0 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative
LFCR logo

Injectable Manufacturing Demand And Regionalization Trends Will Support Steady Long Term Earnings Improvement

Fair Value: US$7.5 4.0% overvalued intrinsic discount
0 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative

Snowflake Analysis

Good value with very low risk.

2 Risks
1 Reward

Lifecore Biomedical, Inc. Key Details

US$128.9m

Revenue

US$88.6m

Cost of Revenue

US$40.3m

Gross Profit

US$84.7m

Other Expenses

-US$44.4m

Earnings

Last Reported Earnings
May 25, 2025
Next Reporting Earnings
n/a
-1.18
31.27%
-34.42%
275.0%
View Full Analysis

About LFCR

Founded
1965
Employees
406
CEO
Paul Josephs
WebsiteView website
www.lifecore.com

Lifecore Biomedical, Inc., together with its subsidiaries, operates as an integrated contract development and manufacturing organization in the United States. The company engages in the manufacture of hyaluronate acid in bulk form; and formulated and filled syringes, cartridges, and vials for injectable products used in treating a range of medical conditions and procedures. It also provides product development services include analytical method development and validation, formulation development, sterile filtration, process scale-up, pilot studies, stability studies, process validation, and production of materials for clinical studies. The company was formerly known as Landec Corporation and changed its name to Lifecore Biomedical, Inc. in November 2022. Lifecore Biomedical, Inc. was founded in 1965 and is headquartered in Chaska, Minnesota.

Recent LFCR News & Updates

Recent updates

No updates